Poolbeg Pharma (POLB) said the US Food and Drug Administration (FDA) has provided supportive feedback following a pre-Investigational New Drug (IND) meeting for POLB 001, its lead asset targeting cancer immunotherapy-induced Cytokine Release Syndrome (CRS).
The clinical-stage biopharmaceutical company said the FDA feedback broadly aligned with its proposed development strategy for POLB 001, including agreement on the proposed primary endpoint for a future Phase 3 trial.
The update marks a regulatory milestone for Poolbeg as it works to advance POLB 001 and engage potential commercial partners. The company said alignment with the FDA provides greater clarity on the route to market and further de-risks the programme.
Poolbeg believes POLB 001 could address a significant unmet need in cancer immunotherapy, where CRS remains a serious complication for some patients undergoing treatment.
Poolbeg’s VP of Regulatory Affairs Bruno Speder said: “We received constructive feedback from the FDA and achieved broad alignment on several important aspects of the development pathway for POLB 001. We believe that POLB 001 has the potential to address a critical unmet need in cancer immunotherapy-induced CRS, and this feedback provides greater clarity as we continue to advance the programme and supports our ongoing partnering discussions.”
View from Vox
This is a meaningful step for Poolbeg as regulatory clarity is often a key consideration for prospective partners. While the asset still has clinical and commercial hurdles ahead, FDA alignment on the proposed development pathway should strengthen confidence in POLB 001’s positioning as Poolbeg looks to unlock partnering value.